Both studies provided endpoint Edinburgh Postnatal Depression Scale (EPDS) scores, and we pooled the data in a metaanalysis. The resulting effect size was homogenous, with a nonsignificant standardized mean difference (combined n = 71, SMD 0.04, 95%CI, -0.43 to 0.51, I2 = 0%). These studies clearly cannot exclude a clinically significant difference in outcome, as medium effect sizes are possible. A sample size of 90 would be necessary to reveal-with a power of 80% and alpha of 5%-a 3-point difference (from 8 to 5, with a common standard deviation of 5) in endpoint EPDS. To demonstrate a 2-point difference, a total of 200 patients would be needed.
In MD, combination treatment has not only been shown to improve short-term response rates but also to boost retention in treatment over the long-term. 5 A combination of psychotherapy and antidepressants have also been favoured in severe postpartum depression 6 and, when offered, women are likely to choose combination over pharmacotherapy alone. 7, 8 However, as argued by Misri and Kendrick, data on psychotherapy is inadequate. Given its potential benefits, in terms of efficacy and adherence, carrying out trials adequately powered to detect meaningful differences, especially in relevant subgroups, such as those with severe forms, is called for at this time.
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Re: Treatment of Perinatal Mood and Anxiety Disorders: A Review
Dear Editor:
We share the assertion made by Misri and Kendrick 1 that serious concerns have been raised about the safety of antidepressant (AD) use in pregnancy. However, it is also our view that the extent of the behavioural teratogenesis of these agents are unclear, and to date and to our knowledge, there have been no prospective, randomized controlled trials to ascertain these effects. Further, studies have shown poorer outcomes for women who were treated with selective seratonin reuptake inhibitors. 2 Electroconvulsive therapy (ECT) has been used successfully to treat depression, even before the advent of ADs, 3 and in fact, the American Psychiatric Association has recommended ECT as a safe and effective treatment during all 3 trimesters of pregnancy. 4 Evidence has shown that patient satisfaction with ECT is more than 80%. 5 We suggest that ECT should be considered as a first-line treatment in pregnant women with severe, persistent, and recurrent depression.
All of the psychotropic medications are excreted in breast milk and the neurobehavioural teratogenesis in the infants exposed to these medications during breastfeeding is unknown. 6 We suggest that ECT is a safe and effective alternative to psychotropic medication in depressed women and their infants during breastfeeding. ECT should strongly be considered and offered at the earliest possible opportunity, as a first-line, nonpharmacological option in depressed, breastfeeding women.
One of the nonpharmacological interventions that has not been reviewed in this article is sleep deprivation. Even though its efficacy has not been fully evaluated in pregnant women, it has been shown to be an effective treatment intervention in depression including those with melancholic symptoms. 7 The Canadian Journal of Psychiatry, Vol 53, No 3, March 2008 W
